Oncology: transforming cancer treatment afficacy

The Nucleotica platform facilitates precise monitoring of therapeutic efficacy in personalized cancer management.

Oncology: <span>transforming</span> cancer treatment afficacy

Overview

Our platform enables pesonalized cancer treatment decisions.

We offer a platform with minimally invasive approaches to optimize the monitoring of cancer treatment response in patients of all ages.

Our solution enables analysis of ctDNA and mutations, helping clinicians make data-driven decisions and tailor treatment plans.

Liquid biopsy analysis.

Tracking MRD

The platform can identify minimal residual disease that may remain after treatment, which is crucial for assessing the risk of relapse and guiding further treatment.

Real-time monitoring.

Liquid biopsy allows monitoring cancer progression and treatment efficacy without invasive procedures.

Early detection - early decision.

By detecting ctDNA in the early stages of cancer, the platform enables making erlier decisions, when treatment options are often more effective and less complex.

Minimally invasive testing.

Liquid biopsy uses blood to detect ctDNA, providing a minimally invasive testingand more comfortable option for patients.

Mutation detection.

Precision mutation identification.

Nucleotica detects mutations in key genes like EGFR, BRAF, PIK3CA, and KRAS, often targeted in personalized cancer therapies.

Comprehensive mutation analysis.

Our system offers panels that detect a range of mutations, including rare genetic changes, giving insights into a patient’s cancer.

Pediatric oncology focus.

Our system is also optimized for pediatric cancers, which often involve different mutations and challenges in treatment compared to adult cancers. Personalized care strategies for children are now within reach with our solution.

Guiding targeted therapy.

By identifying specific mutations, our platform helps guide clinicians in selecting the most appropriate targeted therapies, which are increasingly central to modern cancer treatment.

High sensitivity and accuracy.

Unmatched sensitivity.

Our nanosensor technology ensures high sensitivity, detecting trace ctDNA in the bloodstream. This sensitivity is crucial for accurate cancer monitoring.

Low limit of detection.

The ability to detect low levels of ctDNA means that recurrent cancers in their early or dormant stages can be identified before symptoms arise, providing a significant advantage in clinical outcomes.

Minimal sample amount.

Our system requires only small volumes of blood or other bodily fluids, reducing patient discomfort and enabling easy, repeatable testing.

Rapid and precise results.

Fast turnaround.

Results are delivered quickly, often within hours, ensuring that clinicians can make timely decisions based on the most up-to-date information.

Data-driven decisions.

Direct access to detailed reports and results allows healthcare providers to tailor treatments and adjust strategies immediately based on the latest findings.

Seamless integration.

The platform is designed to integrate smoothly into existing hospital or clinic workflows, providing fast and actionable results without disrupting routine operations.

Impact on Cancer care

Nucleotica can transform cancer diagnosis, monitoring, and treatment, impacting various aspects of care.

Liquid biopsy.

Less invasive: Liquid biopsy reduces discomfort compared to traditional methods, making it more accessible and less traumatic.

Cost-effective: Non-invasive testing cuts the need for costly, time-consuming procedures, making cancer care affordable.

Personalized treatment.

Targeted therapies identify genetic mutations, allowing personalized treatment options that target specific changes in cancer cells, enhancing effectiveness.

Targeted therapies lead to fewer side effects than traditional treatments, enhancing the patient's quality of life during cancer care.

Ongoing Monitoring: ctDNA analysis enables early relapse detection and timely interventions, improving outcomes.

Applications

The Nucleotica platform is transforming cancer care across various areas.

Cancer monitoring and treatment planning.

Monitoring ctDNA levels helps track disease progression, treatment response, and resistance, improving treatment planning.

Customized care based on individual genetic profiles ensures that therapies are specifically targeted to each patient's cancer type.

Cancer risk assesment.

The platform facilitates the early detection of cancers in high-risk individuals, enabling timely intervention and improving long-term survival rates.

Pediatric oncology.

The system provides critical insights for the diagnosis and monitoring of pediatric cancers, ensuring that children receive appropriate, less toxic therapies.

Research and clinical trials.

The platform can be used in research settings to explore new cancer treatments and monitor patients in clinical trials, facilitating better outcomes for drug development and testing.

Nucleotica

Why choose the Nucleotica platform for for personalized cancer treatment?

Early detection.

Our platform offers unmatched precision in identifying genetic susceptibility to cancers, allowing for early intervention and enhancing long-term survival outcomes.

Portability.

Its compact, portable design allows real-time testing in virtually any setting — from hospitals to remote locations — ensuring that diagnostics is accessible to all.

Personalized care.

Through SNP analysis, our platform provides personalized insights into genetic predispositions, enabling tailored prevention and treatment strategies for each patient.

Cost-effective.

By reducing the need for expensive infrastructure and offering fast, affordable diagnostics, our platform is an economical choice for both healthcare providers and patients.

Impactful healthcare.

With the ability to detect risks early, reduce healthcare costs, and improve patient outcomes, the Nucleotica platform is a vital tool in the fight against cancer.

Contact us

Reach out to start your next innovation today.